p53 Signature and Serous Tubal In-situ Carcinoma in Cases of Primary Tubal and Peritoneal Carcinomas and Serous Borderline Tumors of the Ovary

被引:42
|
作者
Leonhardt, Karoline [1 ]
Einenkel, Jens [2 ]
Sohr, Sindy [2 ]
Engeland, Kurt [2 ]
Horn, Lars-Christian [1 ]
机构
[1] Univ Leipzig, Inst Pathol Gynecol & Perinatal Pathol, Div Breast, D-04103 Leipzig, Germany
[2] Univ Leipzig, Dept Obstet & Gynecol, Inst Trier, D-04103 Leipzig, Germany
关键词
Serous tubal carcinoma; Fallopian tube; p53; BRCA; Peritoneal cancer; Ovarian serous borderline tumor; Serous pelvic cancer; PROPHYLACTIC OOPHORECTOMY SPECIMENS; INTRAEPITHELIAL CARCINOMA; FALLOPIAN-TUBE; PATHOLOGICAL FINDINGS; CANDIDATE PRECURSOR; MUTATION CARRIERS; CANCER; BRCA; FIMBRIA; WOMEN;
D O I
10.1097/PGP.0b013e318216d447
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The objective of this study was to evaluate the role of the fimbriated end and nonfimbriated epithelium of fallopian tubes with regard to p53 signature, tubal intraepithelial lesions in transition (TILT), and serous tubal in-situ carcinoma (STIC) in cases of different kinds of serous pelvic cancer. This study immunohistochemically evaluated (by Ki-67 and p53 staining) the presence of p53 signature, TILT lesions, and STIC in 14 consecutive cases of prophylactic salpingo-oophorectomy in women with BRCA-1/2 mutation (bilateral salpingo-oophorectomy), 11 cases of macroscopically inconspicuous adnexae of patients with primary contralateral tubal cancer (TC), 9 cases of primary peritoneal cancer (PPC), and 10 cases of serous ovarian borderline tumors, evaluating the fallopian tubes (using the Sectioning and Extensively Examining the FIMbria protocol), ovarian surface epithelium, and ovarian cortical inclusion cysts. The frequencies of p53 signature, TILT, and STIC were 35.7%, 7.1%, and 0% in cases of prophylactic surgery, 18.2%, 9.1%, and 18.2% in TC, and 11.1%, 0%, and 33.3% in PPC. These precursor lesions were missed during the initial routine screening and were found in the fimbriated end of the fallopian tubes in 94%. In 1 case of PPC, staining for p53 was negative in STIC. The studied adnexal tissue of serous ovarian borderline tumor and ovarian cortical inclusion cysts of all cases showed no alterations according to p53 signature, TILT, or STIC. STIC and p53 signature as precursor lesions of pelvic serous cancer were seen in macroscopically inconspicuous contralateral fallopian tubes in unilateral TC, in patients with elective bilateral salpingo-oophorectomy, and in patients affected by PPC. Therefore, we propose the complete processing of adnexal tissue and the use of step sectioning to establish the correct diagnosis. Immunohistochemistry for p53 and ki-67 may aid in the diagnosis, but is not necessary for routine investigation.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 50 条
  • [31] Long Interspersed Element-1 Expression in Ovarian Cancers and Precancerous Lesions Including Serous Tubal Intraepithelial Carcinomas and p53 Signatures
    Asaka, Shiho
    Pisanic, Thomas
    Wang, Jeff
    Burns, Kathleen
    Wang, Tian-Li
    Shih, le-Ming
    MODERN PATHOLOGY, 2019, 32
  • [32] Micropapillary serous carcinoma, a distinct neoplasm of the ovary: An immunohistochemical and mutational analysis of p53
    Tashiro, H
    Katabuchi, H
    Cho, KR
    Kurman, RJ
    Hedrick, L
    LABORATORY INVESTIGATION, 1996, 74 (01) : 570 - 570
  • [33] Expression of Cox-2, CD34, bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma
    Khalifeh, I
    Munkarah, AR
    Lonardo, F
    Malone, JM
    Morris, R
    Lawrence, WD
    Ali-Fehmi, R
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) : 162 - 169
  • [34] Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors
    Gershenson, DM
    Deavers, M
    Diaz, S
    Tortolero-Luna, G
    Miller, BE
    Bast, RC
    Mills, GB
    Silva, EG
    CLINICAL CANCER RESEARCH, 1999, 5 (12) : 4053 - 4058
  • [35] Clonality of borderline and serous carcinoma of the ovary: Molecular studies identify a monoclonal origin for primary tumors and their implants
    Ning, EMLL
    Teller, LS
    Ricketts, RSJ
    Otis, C
    Sobel, M
    Merino, MJ
    MODERN PATHOLOGY, 2006, 19 : 187A - 187A
  • [36] Clonality of borderline and serous carcinoma of the ovary: Molecular studies identify a monoclonal origin for primary tumors and their implants
    Ning, EMLL
    Teller, LS
    Ricketts, RSJ
    Otis, C
    Sobel, M
    Merino, MJ
    LABORATORY INVESTIGATION, 2006, 86 : 187A - 187A
  • [37] Letter to the Editor on "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" Int J Gynecol Cancer 2015; 25: 1201-1207
    Prat, Jaime
    Young, Robert H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (02) : 226 - 227
  • [38] COMPARISON OF P53 AND MIB-1 EXPRESSION IN BENIGN AND BORDERLINE AREAS OF OVARIAN SEROUS TUMORS
    MARCELLI, A
    DEMOPOULOS, R
    GOSWAMI, S
    MITTAL, K
    LABORATORY INVESTIGATION, 1995, 72 (01) : A93 - A93
  • [39] Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma
    Jarboe, Elke A.
    Pizer, Ellen S.
    Miron, Alexander
    Monte, Nick
    Mutter, George L.
    Crum, Christopher P.
    MODERN PATHOLOGY, 2009, 22 (03) : 345 - 350
  • [40] Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors
    Marcelli, AR
    Demopoulos, RI
    Goswami, S
    Mittal, KR
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1996, 15 (01) : 39 - 44